YANTAI, CHINA / ACCESSWIRE / July 28, 2014 / Bohai Pharmaceuticals Group, Inc. (OTCQB: BOPH), a leading manufacturer and marketer of traditional Chinese medicine (TCM), today said it has updated its company website to include new corporate and industry information.
Bohai’s main site, http://www.bohaipharma.com, also includes a new investor relations section, http://irdirect.net/BOPH/corporate_overview, which features expanded information and news on the company, its products and markets.
The updated site was edited by Bohai’s investor/public relations agency, New York-based Asia IR-PR, which specializes in representing U.S.-listed Chinese public companies to the worldwide financial community.
"We are very excited about our new website," said Bohai chairman and chief executive officer, Mr. Hongwei Qu. "Bohai has been making substantial progress marketing some of our industry's most popular TCMs – including two on China’s Essential Drug List – and we look forward to communicating this progress to our worldwide investors."
Investors wishing to receive Bohai’s corporate communications as they become available may go to http://irdirect.net/BOPH/email_alerts and register under Email Alerts.
Additional information on Bohai may also be found at http://asia-irpr.com/clients/bohai/ and at the company’s featured page on the worldwide investor platform, Company Spotlight: http://www.companyspotlight.com/114569/bohai-pharmaceuticals-group-inc .
Bohai Pharmaceuticals Group
A manufacturer and marketer of traditional Chinese medicine (TCM) in the People’s Republic of China, Bohai offers seven varieties of approved herbal medicines comprising four prescription drugs and three over-the-counter products in six delivery systems. The company reported net income of $19.1 million on revenue of $151.8 million for the year ended June 30, 2013.
Asia IR-PR http://asia-irpr.com/
Founded in 2013, Asia IR-PR is a full-service IR/PR/Media company formed specifically to develop comprehensive communications programs for Asia-based public companies listed on NASDAQ, NYSE, and the HKSE. The principals of Asia IR-PR, with decades of experience in the public markets, have managed and successfully conducted both IR and PR campaigns for over 100 U.S.-listed companies. Based in New York City, Asia IR-PR has in-house analysts and executives fluent in both Mandarin and English in order to best communicate with Chinese management of our listed client companies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of United States securities laws. You should not rely upon forward-looking statements as predictions of future events. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or to changes in our expectations. You should review the factors described in the section entitled "Risk Factors" in our prospectus filed with the SEC and other documents we file from time to time with the SEC. We qualify all of our forward-looking statements by these cautionary statements.
Contacts:
Investors
Jimmy Caplan
Asia IR/PR
512-329-9505
Media
Rick Eisenberg
Asia IR/PR
212-496-6828
SOURCE: Bohai Pharmaceuticals Group, Inc.